Health & Fitness
Health and Fitness
Health and Fitness
Mon, June 7, 2010
Sun, June 6, 2010
Sat, June 5, 2010
Fri, June 4, 2010 BioSante Pharmaceuticals, Inc. To Present at the Annual Needham Healthcare Conference
LINCOLNSHIRE, Ill.--([ BUSINESS WIRE ])--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the Annual Needham Healthcare Conference to be held in the New York Palace Hotel, New York City from June 9-10, 2010.
Stephen M. Simes, BioSantea™s president & CEO, will speak on Wednesday Jun 9 at 11:20 pm ET. He will provide a status report on BioSantea™s portfolio of cancer vaccines in clinical development, as well as an update on LibiGel® (testosterone gel) in clinical development for the treatment of female sexual dysfunction. A live audio webcast of Mr. Simesa™ remarks may be accessed at [ http://www.wsw.com/webcast/needham38/bpa/ ] and a replay will be available at the same link.
About the Needham Healthcare Conference
The 9th Annual Needham Healthcare Conference will be held June 9-10, 2010 at The New York Palace Hotel in New York City. The Conference is a high-impact forum for institutional investors and venture capital firms to hear the latest updates from senior management teams of both public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology and Diagnostics sectors. Over the course of two days, attendees participate in moderated company presentations, as well as expert panels of clinical and industry professionals.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSantea™s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrina" (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development is a portfolio of cancer vaccines (GVAX), two of which have been granted orphan drug designation, currently in several Phase II clinical trials, at minimal cost to BioSante. Other products in development are Bio-T-Gela", a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals (NASDAQ: TEVA) and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLooka"), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: [ www.biosantepharma.com ].
